Antibiotic Stewardship
Antibiotic resistance during and beyond COVID-19.
8 Jul, 2021 | 09:09h | UTCAntibiotic resistance during and beyond COVID-19 – JAC-Antimicrobial Resistance
Study Commentary: Febrile Neutropenia – Procalcitonin vs. MASCC Score.
8 Jul, 2021 | 08:57h | UTCFebrile Neutropenia – Procalcitonin vs MASCC Score – Journal Feed
M-A: Are antimicrobial stewardship interventions effective and safe in long-term care facilities?
8 Jul, 2021 | 08:52h | UTC
RCT: An antibiotic-prescribing feedback to high-volume primary care physicians led to significant reductions in total and prolonged-duration antibiotic prescriptions, as well as drug costs.
7 Jul, 2021 | 08:47h | UTCEffect of Antibiotic-Prescribing Feedback to High-Volume Primary Care Physicians on Number of Antibiotic Prescriptions: A Randomized Clinical Trial – JAMA Internal Medicine (free for a limited period)
Commentary: Studies highlight impact of clinician feedback on antibiotic prescribing – CIDRAP
Commentary on Twitter (thread – click for more)
We conducted a randomized controlled trial of providing antibiotic prescribing feedback to high volume primary care physicians in Ontario, ?? https://t.co/zmF2tvJ5n5
— Kevin Schwartz (@DrKevinSchwartz) July 6, 2021
IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.
28 Jun, 2021 | 09:51h | UTCCo-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis.
25 Jun, 2021 | 10:37h | UTC
Commentary on Twitter
#COVID19 Associated Pulmonary Aspergillosis
?increasing, associated with excess mortality
?complex: colonization + tissue/angio-invasion
?diagnose? bronchoscopy/BAL
?antifungals recommended
?consider discontinuating/tapering steroids in no respondershttps://t.co/HhS6wUfibn pic.twitter.com/CJwE3CEXxn— Intens Care Med (@yourICM) June 23, 2021
RCT: Doxycycline for 7 days superior to single-dose azithromycin for the treatment of rectal chlamydia infection.
25 Jun, 2021 | 10:19h | UTCAzithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Doxycycline Superior to Azithromycin for Asymptomatic Rectal Chlamydia in Men – Physician’s Weekly
Commentary on Twitter
Doxycycline is 20% more efficacious than azithromycin for the treatment of rectal chlamydia. Check out the results of our RCT published today in @NEJM.
Azithromycin or Doxycycline for Asymptomatic Rectal Chlamydia trachomatis | NEJM https://t.co/qpjo8VTg8u
— Jane Hocking (@JHocking01) June 23, 2021
IDSA 2021 focused update guidelines on the management of Clostridioides difficile infection in adults.
25 Jun, 2021 | 10:17h | UTCNews release: IDSA And SHEA Release New Guidelines for Managing Clostridium Difficile Infection – Infectious Diseases Society of America
Commentary on Twitter
????Clinical Practice Guideline @IDSAInfo @SHEA_Epi 2021 Focused Update Guidelines on Management of CDI in Adults
Major update?:for patients with an initial CDI episode, guidelines suggest using fidaxomicin rather than a standard course of vancomycin https://t.co/2iqcoTHqLL pic.twitter.com/2uzZamvkkr— Antibiotic Steward ???Bassam Ghanem (@ABsteward) June 24, 2021
Review | My Treatment Approach to Clostridioides difficile Infection.
24 Jun, 2021 | 09:47h | UTCMy Treatment Approach to Clostridioides difficile Infection – Mayo Clinic Proceedings
WHO Report: Global antimicrobial resistance and use surveillance system.
11 Jun, 2021 | 08:22h | UTCNews Release: Record response to WHO’s call for antimicrobial resistance surveillance reports in 2020 – World Health Organization
Commentary: WHO reveals new global antibiotic resistance data, more concerns – CIDRAP
Commentary on Twitter (thread – click for more)
WHO received over 3⃣ million reports for the Global #AntimicrobialResistance and Use Surveillance System (GLASS)
The more information we have the better placed the ?
is to tackle this increasingly serious health threat.? https://t.co/ccZCzdyZUc
pic.twitter.com/DMuLwVu4rC— World Health Organization (WHO) (@WHO) June 9, 2021
Time-to-positivity in bloodstream infection is not a prognostic marker for mortality: analysis of a prospective multicenter randomized control trial.
8 Jun, 2021 | 09:21h | UTC
Commentary on Twitter
??Analysis Data from RAPIDO RCT
Time to positivity is not associated with mortality, except in Candida spp (longer times associated with worse outcomes), and possibly in Streptococci (shorter times associated with worse outcomes) #IDTwitter #medtwitter https://t.co/v17uT8j7u9— Antibiotic Steward ???Bassam Ghanem (@ABsteward) June 7, 2021
Opinion | “Doctors have been blamed for the rise in black fungus in India, but the COVID treatment guidelines could be contributing” – improper use of antibiotics and higher than usual doses of corticosteroids may be contributing to the emergence of mucormycosis and other fungal co-infections.
6 Jun, 2021 | 23:48h | UTCRelated: The Emergence of COVID-19 Associated Mucormycosis: Analysis of Cases From 18 Countries – The Lancet AND What Is ‘Black Fungus’? And Why Is It Spreading Among India’s COVID Patients? – NPR AND Mucormycosis: The ‘black fungus’ maiming Covid patients in India AND What is mucormycosis, the fungal infection affecting COVID patients in India? – The Conversation
Another study shows a high frequency of antibiotic use among patients hospitalized with Covid-19 (85.2%), despite low rates of confirmed secondary bacterial infections.
4 Jun, 2021 | 10:43h | UTCCommentaries: Very high use of antibiotics in COVID-19 treatment could be reduced – University of Glasgow AND More evidence of frequent antibiotic use noted in COVID patients – CIDRAP AND Covid-19: Antimicrobial use was high during first wave despite bacterial co-infections being rare, study finds – The BMJ
Related: Many hospitalized Covid-19 patients are given antibiotics. That’s a problem – STAT
Commentary on Twitter (thread – click for more)
Our paper on co-infections, secondary infections & antimicrobial use in patients hospitalised with #COVID19 in UK during the 1st wave is out in @LancetMicrobe!@ISARIC1 @CCPUKstudy @CVRinfo @UofGlasgow @EdinburghUni @LivUni @imperialcollege https://t.co/QYU1B2Eyup
A?
— Antonia Ho (@DrToniHo) June 3, 2021
Guideline | Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors.
31 May, 2021 | 08:09h | UTC
RCT: Among children with protracted bacterial bronchitis, a 4-week course of amoxicillin–clavulanate is not better than a 2-week course in achieving clinical cure by 28 days.
31 May, 2021 | 08:02h | UTCCommentary: Four weeks of antibiotics for kids’ chronic cough no better than 2, study finds – CIDRAP
Commentary on Twitter
NEW Research—4 weeks of amoxicillin–clavulanate for children with chronic wet cough and suspected PBB confers little advantage vs 2 weeks in achieving clinical cure by 28 days
RCT from Tom Ruffles & colleagues https://t.co/77w08dZ20z pic.twitter.com/LYgOeJbDX8
— The Lancet Respiratory Medicine (@LancetRespirMed) May 26, 2021
Observational study suggests ceftriaxone is similarly effective to benzylpenicillin for the treatment of neurosyphilis, potentially decreasing the length of hospital stay (mean 13.8 days vs. 8.9 days).
31 May, 2021 | 08:06h | UTCCeftriaxone compared with benzylpenicillin in the treatment of neurosyphilis in France: a retrospective multicentre study – The Lancet Infectious Diseases (link to abstract – $ for full-text)
RCT: Among patients with prosthetic joint infection, antibiotic therapy for 6 weeks was NOT shown to be noninferior to antibiotic therapy for 12 weeks and resulted in a higher percentage of patients with unfavorable outcomes.
27 May, 2021 | 08:20h | UTCAntibiotic Therapy for 6 or 12 Weeks for Prosthetic Joint Infection – New England Journal of Medicine (link to abstract – $ for full-text)
M-A: Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens – The pooled prevalence of co-infection at the time of a SARS-CoV-2 diagnosis was 19%, and that of superinfection was 24%.
21 May, 2021 | 08:48h | UTC
A pharmacist-led penicillin allergy assessment program can delabel many “penicillin allergic” patients through allergy histories and penicillin skin testing. The program was associated with reduced use of high Clostridioides difficile infection–risk antibiotics.
20 May, 2021 | 08:30h | UTC
Commentaries on Twitter
??? @jamanetworkopen
Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a 3ry Care Hospital
Phase 1 : Allergy histories
Phase 2 :Allergy histories +Penicillin Skin Testing #IDTwitter https://t.co/pZfVf8TJIn pic.twitter.com/2VvnaCayqj— Antibiotic Steward ???Bassam Ghanem (@ABsteward) May 13, 2021
This cross-sectional study found pharmacist-driven allergy assessments may help improve antibiotic selection and clinical outcomes for patients and hospitals https://t.co/io5LcU9U9U
— JAMA Network Open (@JAMANetworkOpen) May 13, 2021
M-A: Compared to cefazolin alone, pre-incision cefazolin + adjunctive prophylaxis with macrolides or metronidazole significantly reduces the incidence of post-cesarean surgical site infection and hospital stay.
20 May, 2021 | 08:19h | UTCPre-incision Adjunctive Prophylaxis for Cesarean Sections: A Systematic Review and Meta-analysis – American Journal of Obstetrics & Gynecology (link to abstract – $ for full-text)
M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.
18 May, 2021 | 07:50h | UTC
RCT: Among adults with idiopathic pulmonary fibrosis, antimicrobial therapy with co-trimoxazole or doxycycline is not associated with improved outcomes.
12 May, 2021 | 08:37h | UTCEffect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
Among adults with idiopathic pulmonary fibrosis, addition of co-trimoxazole or doxycycline compared with usual care did not significantly improve the time to nonrespiratory hospitalization or death https://t.co/t6WQ2sifx0
— JAMA (@JAMA_current) May 11, 2021
RCT: Prophylactic closed incision negative pressure wound therapy reduces (difference close to statistical significance; P=0.06) the risk of surgical site infection in obese women undergoing cesarean section.
7 May, 2021 | 08:24h | UTC
ATS Guideline: Nucleic acid–based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia – Testing should be considered only in patients with severe CAP and in immunocompromised patients
5 May, 2021 | 08:28h | UTCNews Release: New clinical practice guideline on community acquired pneumonia – American Thoracic Society
Study: Most patients who develop a non-IgE-mediated hypersensitivity reaction to nafcillin can be safely treated with cefazolin
4 May, 2021 | 08:36h | UTC
Commentary on Twitter
New case series found 90% tolerated switching to cefazolin out of 80 patients who experienced non-IgE hypersensitivity reactions to nafcillin.https://t.co/YbFeWS4n4k
Our previous metas-analysis https://t.co/sJBjrx4a3r found higher odds of these reactions with nafcillin. pic.twitter.com/SIWcSuPcct— Antibiotic Tweets ? (@khalideljaaly) April 28, 2021